Table 4 Subgroup analyses with respect to duration of bisphosphonates.
From: Bisphosphonates and risk of cancers: a systematic review and meta-analysis
Subgroupsa | <1 year | ≥1 year | ||||||
|---|---|---|---|---|---|---|---|---|
Number of studies | RR (95% CI) | I2 | P for heterogeneity | Number of studies | RR (95% CI) | I2 | P for heterogeneity | |
Oesophageal cancer | 5 | 1.22 (0.83–1.78) | 66% | 0.02 | 5 | 0.99 (0.79–1.24) | 26% | 0.25 |
Gastric cancer | 3 | 1.11 (0.91–1.34) | 0% | 0.56 | 3 | 1.15 (0.75–1.75) | 76% | 0.02 |
Colorectal cancer | 5 | 1.04 (0.88–1.24) | 65% | 0.02 | 7 | 0.84 (0.71–1.04) | 89% | <0.01 |
Bladder cancer | 2 | 1.59 (0.53–4.75) | 74% | 0.05 | 2 | 0.98 (0.64–1.48) | 23% | 0.25 |
Pancreas cancer | 2 | 1.25 (0.44–3.52) | 89% | <0.01 | 2 | 0.99 (0.58–1.68) | 65% | 0.09 |
Renal cell carcinoma | 1 | 1.06 (0.73–1.53) | NA | NA | 1 | 1.10 (0.78–1.56) | NA | NA |
Breast cancer | 4 | 0.90 (0.84–0.97) | 0% | 0.88 | 5 | 0.78 (0.63–0.98) | 92% | <0.01 |
Endometrial cancer | 2 | 0.89 (0.61–1.30) | 0% | 0.34 | 2 | 0.55 (0.27–1.12) | 94% | <0.01 |
Ovarian cancer | 2 | 0.75 (0.21–2.73) | 43% | 0.18 | 2 | 0.73 (0.41–1.30) | 90% | <0.01 |
Prostate cancer | 1 | 0.90 (0.79–1.02) | NA | NA | 1 | 0.85 (0.76–0.95) | NA | NA |
Lung cancer | 1 | 1.10 (1.00–1.21) | NA | NA | 1 | 1.01 (0.92–1.10) | NA | NA |
Melanoma | 1 | 0.90 (0.73–1.10) | NA | NA | 1 | 1.09 (0.92–1.29) | NA | NA |
